Samsung BioLogics filed a patent invalidation lawsuit against multinational drug maker Lonza.
According to related industries on July 5, Samsung BioLogics filed a lawsuit to the Korean Patent Tribunal for the invalidation of Swiss pharmaceutical company Lonza’s patent on a mammalian gene expression vector including the first intron and mCMV promoter of a major early hCMV gene on July 3. Lonza is a leading company which is engaging in both CMO and CDO business, accounting for 80 to 90 percent of the global CDO market.
Through this lawsuit, Samsung BioLogics threw its hat in the ring to have a duel with Lonza not only in the CMO field but in the CDO field.
The patent opposed by Samsung BioLogics became nominal as the patent was given up in the United States, was considered withdrawn in Europe, and rejected in Japan. Samsung filed this lawsuit in order to eliminate unfair entry barriers of the Korean bio industry as the company entered the CDO business in earnest, a Samsung BioLogics representative explained.